As with other incretin-based therapies, the most commonly reported adverse effects of retatrutide in Phase 2 trials were gastrointestinal in nature (Jastreboff et al., NEJM , 2023)
This is the time when the gastrointestinal side effects of these agents, namely nausea, anorexia and some vomiting, are most evident
Structurally similar to fructose, allulose provides approximately 0.4 kilocalories per gramabout 10% of the energy content of regular sugarand is minimally metabolised by the human body
The extended-release formulation of Exenatide provided in Bydureon BCise sets it apart
Long-term improvements in pulmonary function 5 years after bariatric surgery
Contributed by Kendra Dombroski, M.S